[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2418
1. Korolenko TA, Filatova TG, Cherkanova MS, Khalikova TA, Bravve IIu: [Cystatins: cysteine proteases regulation and disturbances in tumors and inflammation]. Biomed Khim; 2008 Mar-Apr;54(2):210-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with hemoblastoses (lymphoma, lymphogranulomatosis) increased serum cystatin C concentration was normalized after effective antitumor therapy.
  • [MeSH-major] Cystatins / analysis. Hodgkin Disease / metabolism. Inflammation / metabolism. Leukemia / metabolism. Lymphoma, Non-Hodgkin / metabolism. Myocardial Ischemia / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers / analysis. Child. Cystatin C. Humans. Immunoenzyme Techniques. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522223.001).
  • [ISSN] 2310-6972
  • [Journal-full-title] Biomedit︠s︡inskai︠a︡ khimii︠a︡
  • [ISO-abbreviation] Biomed Khim
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins
  •  go-up   go-down


2. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol; 2008 Jan 20;26(3):455-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
  • PURPOSE: To compare the clinical outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), overall survival (OS), and progression-free survival (PFS) in patients with relapsed Hodgkin's lymphoma (HL) treated with reduced-intensity conditioning (RIC) or myeloablative conditioning followed by allogeneic stem-cell transplantation (alloSCT).
  • The development of chronic graft-versus-host disease (GVHD) significantly decreased the incidence of relapse, which translated into a trend for a better PFS.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / immunology. Hodgkin Disease / therapy. Neoplasm Recurrence, Local / immunology. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Graft vs Leukemia Effect. Humans. Incidence. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Aug 20;26(24):4045-6; author reply 4046-7 [18711200.001]
  • (PMID = 18086796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


3. Terenziani M, Piva L, Meazza C, Gandola L, Cefalo G, Merola M: Oophoropexy: a relevant role in preservation of ovarian function after pelvic irradiation. Fertil Steril; 2009 Mar;91(3):935.e15-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report on our experience with girls and young women who received treatment for Hodgkin lymphoma, underwent prior oophoropexy to preserve their ovarian function, and subsequently gave birth.
  • PATIENT(S): Eleven girls given treatment for Hodgkin lymphoma and undergoing bilateral ovarian transposition at a median age of 13 years.
  • [MeSH-major] Gynecologic Surgical Procedures. Hodgkin Disease / radiotherapy. Infertility, Female / prevention & control. Laparoscopy. Ovary / surgery. Radiation Injuries / prevention & control
  • [MeSH-minor] Abortion, Spontaneous. Adolescent. Adult. Child. Female. Humans. Live Birth. Pelvis. Pregnancy. Pregnancy Rate. Radiotherapy / adverse effects. Retrospective Studies. Young Adult


Advertisement
4. Barista I, Varan A, Ozyar E: Bimodal age distribution in Hodgkin's disease and nasopharyngeal carcinoma. Med Hypotheses; 2007;68(6):1421
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bimodal age distribution in Hodgkin's disease and nasopharyngeal carcinoma.
  • [MeSH-major] Carcinoma / epidemiology. Hodgkin Disease / epidemiology. Models, Statistical. Nasopharyngeal Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Cell Transformation, Neoplastic / genetics. Epstein-Barr Virus Infections / epidemiology. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / classification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / physiology. Humans. Incidence. Middle Aged. Time Factors. Virus Latency

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196754.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Scotland
  •  go-up   go-down


5. Rodríguez-Vigil B, Gómez-León N, Pinilla I, Hernández-Maraver D, Coya J, Martín-Curto L, Madero R: PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med; 2006 Oct;47(10):1643-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
  • This study prospectively compares the agreement between contrast-enhanced full-dose PET/CT and unenhanced low-dose PET/CT in lesion detection and initial staging of Hodgkin's disease and non-Hodgkin's lymphoma.
  • METHODS: Forty-seven biopsy-proven lymphoma patients underwent a 18F-FDG PET/CT study that included unenhanced low-dose CT and enhanced full-dose CT for initial staging.
  • Lesion detection, number of sites affected in each anatomic region, and disease stage were assessed.
  • Agreement between the 2 types of PET/CT was almost perfect for disease stage (kappa = 0.92; P < 0.001).
  • CONCLUSION: Our study showed a good correlation between unenhanced low-dose PET/CT and contrast-enhanced full-dose PET/CT for lymph node and extranodal disease in lymphomas, suggesting that unenhanced low-dose PET/CT might suffice in most patients as the only imaging technique for the initial staging of lymphomas, reserving diagnostic CT for selected cases.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Prospective Studies. Radiation Dosage. Radiography, Abdominal. Sclerosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17015900.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Haase R, Sauer H, Dagwadordsch U, Foell J, Lieser U: Successful treatment of Bacillus cereus meningitis following allogenic stem cell transplantation. Pediatr Transplant; 2005 Jun;9(3):338-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 19-yr-old boy, who received an allogeneic stem cell transplantation for the second relapse of Hodgkin's disease.
  • [MeSH-major] Bacillus cereus. Hodgkin Disease / surgery. Meningitis, Bacterial / therapy. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Catheterization, Central Venous. Humans. Male

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910391.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


7. Moskowitz A, Nolan C, Lis E, Castro-Malaspina H, Perales MA: Posterior reversible encephalopathy syndrome due to sirolimus. Bone Marrow Transplant; 2007 May;39(10):653-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Female. Graft vs Host Disease / prevention & control. Hodgkin Disease / therapy. Humans. Magnetic Resonance Imaging. Peripheral Blood Stem Cell Transplantation. Syndrome

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384653.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


8. Younes A: Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2009;:507-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
  • Although classical Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging.
  • Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities.
  • New drugs and novel treatment strategies that are based on our understanding of the disease biology and signaling pathways are needed to improve treatment outcome for these patients.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008236.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Drugs, Investigational; 0 / Enzyme Inhibitors; 0 / Hydroxamic Acids; 0 / Immunoconjugates; 0 / Immunotoxins; 0 / Indoles; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / cAC10-vcMMAE; 9647FM7Y3Z / panobinostat
  • [Number-of-references] 118
  •  go-up   go-down


9. Ohsawa M, Fukushima H, Ikura Y, Inoue T, Shirai N, Sugama Y, Suekane T, Kitabayashi C, Nakamae H, Hino M, Ueda M: Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis. Leuk Lymphoma; 2006 Sep;47(9):1863-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis.
  • Although many studies have revealed the association between cyclooxygenase-2 (COX-2) and carcinogenesis, the association between COX-2 and Hodgkin's lymphoma (HL) remains unknown.
  • Hodgkin and Reed - Sternberg (HRS) cells with COX-2 expression were scored as 0 = no staining; 1 = <25% of cells staining; 2 = 25-49%; 3 = 50-75%; and 4 = > or =75%.
  • [MeSH-major] Cell Proliferation. Cyclooxygenase 2 / metabolism. Hodgkin Disease / enzymology. Membrane Proteins / metabolism. Neovascularization, Pathologic. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064999.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


10. Seshadri T, Gook D, Lade S, Spencer A, Grigg A, Tiedemann K, McKendrick J, Mitchell P, Stern C, Seymour JF: Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer; 2006 Apr 10;94(7):1007-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield.
  • Ovarian cryopreservation is a promising technique to preserve fertility in women with Hodgkin lymphoma (HL) treated with chemotherapy.
  • Disease status and preharvest chemotherapy details were obtained on 24 patients.
  • Seven of 24 patients had infradiaphragmatic disease at time of harvest.
  • In conclusion, subclinical involvement of HL has not been identified in ovarian tissue, even when patients have infradiaphragmatic disease.
  • [MeSH-major] Cryopreservation. Hodgkin Disease. Infertility, Female / prevention & control. Oocytes. Reproductive Techniques, Assisted. Tissue Preservation
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunohistochemistry. Ovarian Follicle / pathology. Ovarian Follicle / physiology. Retrospective Studies. Vinblastine / administration & dosage


11. Al-Mulhim FA: Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma. Saudi Med J; 2005 Jan;26(1):31-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of pelvic and femoral bones for detection of bone marrow infiltration in patients with non-Hodgkins lymphoma.
  • OBJECTIVE: Detection of the residual bone marrow (BM) involvement is essential in treatment of patients with non-Hodgkin's lymphoma (NHL).
  • This study was conducted to determine the advantage of femoral marrow MRI as a non-invasive technique over bilateral iliac crest BM biopsies in detecting BM infiltration before treatment and residual disease after completion of treatment.
  • [MeSH-major] Bone Marrow / pathology. Femur / pathology. Lymphoma, Non-Hodgkin / pathology. Magnetic Resonance Imaging. Pelvis / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Saudi Med J. 2005 May;26(5):898
  • (PMID = 15756349.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


12. Stoneham S, Ashley S, Pinkerton R, Hewitt M, Wallace WH, Shankar AG, Children's Cancer and Leukaemia Group: Hodgkin's lymphoma in children aged 5 years or less - the United Kingdom experience. Eur J Cancer; 2007 Jun;43(9):1415-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in children aged 5 years or less - the United Kingdom experience.
  • PURPOSE: The aim of this study is to describe the natural history of Hodgkin's Lymphoma (HL) in a large unselected group of children aged 5 years or below at diagnosis, who were treated on a standard treatment programme in the United Kingdom between 1982 and 2000.
  • METHODS: Eighty-one unselected children with HL aged 5 years or under at diagnosis, treated on the United Kingdom Children's Cancer Study Group (UKCCSG) Hodgkin's trials HD1 (1982-1992) and HD2 (1992-2000), were included in the study.
  • RESULTS: Sixty-one patients (81%) presented with early stage disease (n=66).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy / mortality. Disease-Free Survival. Female. Great Britain. Humans. Male. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Treatment Failure

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509875.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Delanian S, Pradat PF: Posteriori conformal radiotherapy using three-dimensional dosimetric reconstitution in a survivor of adult-onset Hodgkin's disease for definitive diagnosis of lower motor neuron disease. J Clin Oncol; 2010 Oct 20;28(30):e599-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posteriori conformal radiotherapy using three-dimensional dosimetric reconstitution in a survivor of adult-onset Hodgkin's disease for definitive diagnosis of lower motor neuron disease.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Imaging, Three-Dimensional. Motor Neuron Disease / diagnosis. Radiation Injuries / diagnosis. Radiographic Image Interpretation, Computer-Assisted. Radiotherapy, Conformal / adverse effects. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Motor neuron disease.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20713856.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, de Sanjosé S, Hughes AM, Cerhan JR, Skibola DR, Purdue M, Kane E, Lan Q, Foretova L, Schenk M, Spinelli JJ, Slager SL, De Roos AJ, Smith MT, Roman E, Cozen W, Boffetta P, Kricker A, Zheng T, Lightfoot T, Cocco P, Benavente Y, Zhang Y, Hartge P, Linet MS, Becker N, Brennan P, Zhang L, Armstrong B, Smith A, Shiao R, Novak AJ, Maynadie M, Chanock SJ, Staines A, Holford TR, Holly EA, Rothman N, Wang SS: Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol; 2010 Feb 01;171(3):267-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium.
  • In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk.
  • Consistent with previous findings, odds ratios were increased for "new" participant TNF -308A carriers (NHL: per-allele odds ratio (OR(allelic)) = 1.10, P(trend) = 0.001; diffuse large B-cell lymphoma (DLBCL): OR(allelic) = 1.23, P(trend) = 0.004).
  • In the combined population, odds ratios were increased for TNF -308A carriers (NHL: OR(allelic) = 1.13, P(trend) = 0.0001; DLBCL: OR(allelic) = 1.25, P(trend) = 3.7 x 10(-6); marginal zone lymphoma: OR(allelic) = 1.35, P(trend) = 0.004) and LTA 252G carriers (DLBCL: OR(allelic) = 1.12, P(trend) = 0.006; mycosis fungoides: OR(allelic) = 1.44, P(trend) = 0.015).
  • Results suggested associations between IL10 -3575T>A and DLBCL (P(trend) = 0.02) and IL10 -1082A>G and mantle cell lymphoma (P(trend) = 0.04).
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphotoxin-alpha / genetics. Polymorphism, Single Nucleotide. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Australia / ethnology. Canada / ethnology. Case-Control Studies. Europe / ethnology. European Continental Ancestry Group / genetics. Female. Genetic Predisposition to Disease. Humans. Interleukin-10 / genetics. International Agencies. Male. Middle Aged. Risk Factors. United States / ethnology. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):316-27 [12915497.001]
  • [Cites] Cancer Causes Control. 2004 Sep;15(7):657-63 [15280623.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(3):1233-7 [2105500.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1517-27 [8163935.001]
  • [Cites] Eur J Immunogenet. 1997 Feb;24(1):1-8 [9043871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9 [9096369.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Blood. 2005 Jul 15;106(2):668-72 [15811955.001]
  • [Cites] Scand J Rheumatol. 2005 Mar-Apr;34(2):114-21 [16095006.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 2;97(21):1616-8 [16264183.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D617-21 [16381944.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Am J Epidemiol. 2006 Jul 1;164(1):47-55 [16731576.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):180-3 [16740140.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Haematologica. 2007 Jul;92(7):960-9 [17606447.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2767-75 [17722095.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4455-63 [17827388.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2062-70 [18167059.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] PLoS One. 2008;3(7):e2816 [18636124.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3161-9 [18990758.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2122-9 [15248209.001]
  • [Cites] J Leukoc Biol. 1999 Oct;66(4):562-6 [10534109.001]
  • [Cites] Nature. 2001 May 31;411(6837):603-6 [11385577.001]
  • [Cites] Genet Epidemiol. 2002 Nov;23(4):426-43 [12432508.001]
  • [Cites] Tissue Antigens. 2003 Jul;62(1):72-5 [12859597.001]
  • [CommentIn] Scand J Immunol. 2011 Feb;73(2):154-5 [21198757.001]
  • (PMID = 20047977.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62006; United States / NCI NIH HHS / CA / R01 CA122663-01; United States / NCI NIH HHS / CA / CA89745; Canada / Canadian Institutes of Health Research / / 93100; Canada / Canadian Institutes of Health Research / / 86528; United States / NCI NIH HHS / CA / R01 CA122663-04; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / R01 CA104682-05A2; United States / NCI NIH HHS / CA / CA92153; United States / NCI NIH HHS / CA / CA87014; United States / NCI NIH HHS / CA / R01 CA122663; United States / Intramural NIH HHS / / ; Canada / Canadian Institutes of Health Research / / ; United States / NCI NIH HHS / CA / R01 CA122663-03; United States / NCI NIH HHS / CA / R01 CA104682; United States / NCI NIH HHS / CA / R01 CA092153; United States / NCI NIH HHS / CA / R01 CA122663-02; United States / NCI NIH HHS / CA / R01 CA087014; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CA / CA104862; United States / NCI NIH HHS / CA / R01 CA045614; United States / NCI NIH HHS / CA / R03 CA089745
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  • [Other-IDs] NLM/ PMC2842204
  •  go-up   go-down


15. Munir N, Bradley PJ: Diagnosis and management of neoplastic lesions of the submandibular triangle. Oral Oncol; 2008 Mar;44(3):251-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent primary lesions were malignant non-Hodgkin lymphoma (n=22), adenoid cystic carcinoma (n=9) and mucoepidermoid carcinoma (n=9).
  • Benign tumours manifest a mild course of disease and have an excellent prognosis following adequate excision.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Child. Female. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Retrospective Studies. Submandibular Gland Neoplasms / diagnosis. Submandibular Gland Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17467329.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Chen YB, Rahemtullah A, Breeden E, Hochberg EP: Bleomycin-induced flagellate erythema. J Clin Oncol; 2007 Mar 1;25(7):898-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Hodgkin Disease / drug therapy. Humans. Male

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327612.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


17. Bartlett NL: Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematology Am Soc Hematol Educ Program; 2005;:245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.
  • Autologous stem cell transplant remains the standard of care for relapsed Hodgkin lymphoma (HL).
  • For patients with chemo-refractory disease at relapse and those failing autologous transplant, the long-term prognosis remains poor.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304388.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


18. Nangalia J, Smith H, Wimperis JZ: Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma; 2008 Aug;49(8):1530-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support.
  • We reviewed the outcome of 24 patients with early and advanced stage Hodgkin lymphoma (HL) treated with ABVD chemotherapy (263 treatment deliveries) without the use of G-CSF over a 3-year period.
  • At a median follow up of 17.5 months, one patient had progressive disease requiring intensive treatment and the remainder were in remission post-treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemoprevention / economics. Granulocyte Colony-Stimulating Factor / economics. Hodgkin Disease / drug therapy. Neutropenia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Bacterial Agents. Antibiotic Prophylaxis. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Incidence. Leukocyte Count. Male. Middle Aged. Retrospective Studies. Sepsis. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766966.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 11056-06-7 / Bleomycin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


19. Busia A, Laffranchi A, Viviani S, Bonfante V, Villani F: Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Anticancer Res; 2010 Oct;30(10):4381-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease.
  • The majority of patients with Hodgkin's disease can be cured by combination of polychemotherapy and radiotherapy (RT) that can produce late toxic pulmonary and cardiac effects which often remain at a subclinical level.
  • PATIENTS AND METHODS: We investigated 147 patients suffering from Hodgkin's disease after a follow-up of at least 5 years from the completion of CT-RT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiovascular Diseases / etiology. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lung Diseases / etiology. Radiation Injuries / etiology
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Combined Modality Therapy / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Mechlorethamine / administration & dosage. Mechlorethamine / adverse effects. Middle Aged. Oxygen Consumption / drug effects. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Radiotherapy / adverse effects. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036768.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 3Z8479ZZ5X / Epirubicin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol; MOPP-ABV protocol; VEBEP regimen
  •  go-up   go-down


20. Gonzalez QH, Heslin MJ, Dávila-Cervantes A, Alvarez-Tostado J, de los Monteros AE, Shore G, Vickers SM: Primary colonic lymphoma. Am Surg; 2008 Mar;74(3):214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colonic lymphoma.
  • Surgical resection of primary colonic lymphoma can be an important therapeutic tool.
  • From January 1990 to June 2002, a total of 15 patients with primary colonic lymphoma were identified from the tumor registry at University of Alabama at Birmingham and retrospectively reviewed under Institutional Review Board approved protocol.
  • Differences in survival were evaluated by the log-rank test and the interval of disease-free survival was calculated using the Kaplan-Meier method.
  • Concomitant colorectal disease was present in one patient with ulcerative colitis.
  • Preoperative diagnosis of lymphoma was made in 13 patients (87%) with colonoscopy and biopsy.
  • Only one patient had a history of lymphoproliferative disease and exposure to radiation.
  • The most common disease location was the cecum (60%), followed by the right colon (27%), and the sigmoid colon (13%).
  • According to the clinical classification of primary non-Hodgkin lymphoma (NHL) of the gastrointestinal tract (Lugano, 1993) all patients corresponded to stage IE.
  • Surgical resection of localized, primary colonic lymphoma provides excellent local disease control and should be considered a primary treatment option.
  • The role of chemotherapy remains controversial depending on the grade, stage, and extension of residual disease.
  • [MeSH-major] Colonic Neoplasms / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Colectomy / methods. Female. Humans. Length of Stay / statistics & numerical data. Male. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376684.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Das P, Ng AK, Stevenson MA, Mauch PM: Clinical course of thoracic cancers in Hodgkin's disease survivors. Ann Oncol; 2005 May;16(5):793-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical course of thoracic cancers in Hodgkin's disease survivors.
  • BACKGROUND: Hodgkin's disease survivors have a high risk of subsequently developing thoracic cancers.
  • Our goal was to evaluate the prognosis and treatment outcomes of thoracic cancers after Hodgkin's disease.
  • PATIENTS AND METHODS: Thirty-three patients treated for Hodgkin's disease at Harvard-affiliated hospitals subsequently developed small-cell lung carcinoma, non-small-cell lung carcinoma (NSCLC) or mesothelioma.
  • Information was obtained from medical records about the initial treatment for Hodgkin's disease, any salvage therapy, smoking history, and the stage, histology, treatment and survival for thoracic cancers.
  • The median time between diagnosis of Hodgkin's disease and diagnosis of thoracic cancer was 17.3 years (range 1.2-27.9 years).
  • Among patients with NSCLC and a known stage, 85% presented with stage III or stage IV disease.
  • CONCLUSIONS: Most patients with thoracic cancers after Hodgkin's disease have a history of exposure to risk factors and present at an advanced stage.
  • Patients with thoracic cancers after Hodgkin's disease have a poor survival.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802277.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


22. de Wildt SN, Taguchi N, Koren G: Unintended pregnancy during radiotherapy for cancer. Nat Clin Pract Oncol; 2009 Mar;6(3):175-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 27-year-old woman with upper mediastinum stage IIA Hodgkin lymphoma was treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Mediastinal Neoplasms / radiotherapy. Pregnancy Complications, Neoplastic / radiotherapy. Pregnancy, Unplanned. Prenatal Exposure Delayed Effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Counseling. Female. Fetus. Humans. Pregnancy. Pregnancy Outcome. Pregnancy Trimester, First. Radiation Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Assessment

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174775.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Lake A, Shield LA, Cordano P, Chui DT, Osborne J, Crae S, Wilson KS, Tosi S, Knight SJ, Gesk S, Siebert R, Hay RT, Jarrett RF: Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer; 2009 Sep 15;125(6):1334-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.
  • A consistent feature of the Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) is the constitutive activation of NF-kappaB transcription factors.
  • [MeSH-major] DNA-Binding Proteins / genetics. Epstein-Barr Virus Infections / genetics. Herpesvirus 4, Human / physiology. Hodgkin Disease / genetics. I-kappa B Proteins / genetics. Mutation / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Comparative Genomic Hybridization. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • (PMID = 19507254.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / I-kappa B Proteins; 139874-52-5 / NF-kappaB inhibitor alpha
  •  go-up   go-down


24. Simon Z, Ress Z, Toldi J, Trauninger A, Miltényi Z, Illés A: Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility? Int J Hematol; 2009 May;89(4):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility?
  • With Hodgkin lymphoma (HL), other (autoimmune) diseases may occasionally occur or associate, whereas as a late treatment-complication, second tumour may develop.
  • In 2000 Graves's disease, in 2001 myasthenia gravis was diagnosed, which showed resistance for immunosuppressant drugs, thus plasmapheresis, intravenous immunoglobulin treatments were applied.
  • The disease showed progression despite the chemotherapy applied and the patient died in 2007 due to respiratory failure.
  • Association of Hodgkin lymphoma, and two antibody-mediated autoimmune diseases, Graves' disease and myasthenia gravis, is rare and has not yet been reported in the literature.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. Graves Disease / complications. Hodgkin Disease / complications. Myasthenia Gravis / complications. Neurofibrosarcoma / radiotherapy
  • [MeSH-minor] Adult. Autopsy. Fatal Outcome. Female. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed


25. Niitsu N, Okamoto M, Miura I, Hirano M: Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia; 2009 Apr;23(4):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.
  • Diffuse large B-cell lymphoma (DLBCL) having both t(14;18) and 8q24 translocations is rare.
  • A total of 1972 patients with non-Hodgkin's lymphoma were treated in the Adult Lymphoma Treatment Study Group (ALTSG) from 1998 to 2007.
  • Nineteen cases of de novo DLBCL with the dual translocation were identified.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-myc / genetics. Translocation, Genetic
  • [MeSH-minor] B-Lymphocytes / pathology. Bone Marrow / pathology. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase. Lymphoma, Non-Hodgkin. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151788.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


26. Atypical lymphocytes in Hodgkin disease. Blood; 2008 Jun 1;111(11):5416
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical lymphocytes in Hodgkin disease.
  • [MeSH-major] Hodgkin Disease / complications. Immunocompromised Host. Lymphocytes / pathology. Toxoplasmosis / immunology
  • [MeSH-minor] Adult. Animals. Anti-Bacterial Agents / therapeutic use. Cats. Female. Humans. Lymphocyte Count

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Toxoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533283.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


27. Massardo V T, Canessa G J, Jofré M MJ, González E P, Humeres A P, Sierralta G P: [Role of 18Fluorine-deoxyglucose (FDG) positron emission tomography in the management of lymphomas]. Rev Med Chil; 2006 Jul;134(7):910-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Utilidad de la deoxiglucosa marcada con flúor-18 (FDG) en el manejo de los linfomas.
  • It has an excellent diagnostic yield in Hodgkin disease as well as in most non Hodgkin lymphomas.
  • The main differences and advantages of FDG versus gallium-67 in lymphoma are also discussed, as well as the initial local experience with the technique in lymphoma patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Gallium Radioisotopes. Humans. Male. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130976.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 54
  •  go-up   go-down


28. Papalas JA, Van Mater D, Wang E: Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young. Am J Dermatopathol; 2010 Dec;32(8):821-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyogenic variant of primary cutaneous anaplastic large-cell lymphoma: a lymphoproliferative disorder with a predilection for the immunocompromized and the young.
  • Cutaneous anaplastic large-cell lymphoma belongs to the class of primary cutaneous CD30-positive lymphoproliferative disorders.
  • We describe 2 cases (one which clinically presented as cellulitis, and another arising in a patient with Hodgkin lymphoma) and review the clinicopathologic features of cases reported in the literature.
  • Ten percent of patients experience extracutaneous disease progression and 18% of patients are dead at 10 months.
  • In the clinical context of a progressive ulcerating lesion in younger or immunocompromized patients, it is important for the pathologist when presented with a skin specimen demonstrating a neutrophil-rich inflammatory background to include the pyogenic variant of anaplastic large-cell lymphoma.
  • [MeSH-major] Immunocompromised Host. Lymphoma, Primary Cutaneous Anaplastic Large Cell / immunology. Neutrophils / immunology. Skin / immunology. Skin Neoplasms / immunology
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Young Adult


29. Omlin AG, Mühlemann K, Fey MF, Pabst T: Pneumococcal vaccination in splenectomised cancer patients. Eur J Cancer; 2005 Aug;41(12):1731-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Splenectomy was performed in 54% because of Hodgkin lymphoma.
  • In conclusion, patients splenectomised at a young age because of Hodgkin lymphoma are the key group at risk for insufficient pneumococcal vaccination.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hodgkin Disease / complications. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026979.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pneumococcal Vaccines
  •  go-up   go-down


30. Ritchie D, Hermans I, Yang J, Walton J, Matthews K, Carter J, Findlay M, Dady P, Rawson P, Ronchese F: Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leuk Lymphoma; 2006 Apr;47(4):675-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study demonstrates that autologous dendritic cell vaccines can be successfully produced from patients with advanced disease and be delivered without significant toxicity.
  • These results provide further evidence for the use of immunotherapy in the management of B-cell malignancies, but also suggest that sustained responses may only be possible in patients with low bulk disease early in the disease course.
  • [MeSH-major] B-Lymphocytes / metabolism. Cancer Vaccines / chemistry. Dendritic Cells / cytology. Immunotherapy / methods. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Peptides / chemistry. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Apr;47(4):577-9 [16886270.001]
  • (PMID = 16690526.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Peptides
  •  go-up   go-down


31. Tsartsidze E, Betaneli M, Sharikadze N, Shavidze N, Seskuria N: Treatment of aggressive non-Hodgkin's lymphomas. Georgian Med News; 2007 Apr;(145):30-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Humans. Middle Aged. Prognosis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525494.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


32. Béchade D, Durand X, Desramé J, Rambelo A, Corberand D, Baranger B, Farge D, Algayres JP: [Etiologic spectrum of mesenteric panniculitis: report of 7 cases]. Rev Med Interne; 2007 May;28(5):289-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Profil étiologique des panniculites mésentériques: à propos de sept cas.
  • An associated disease was identified in 4 cases: breast cancer (1), non-Hodgkin's lymphoma based on peripheric lymph nodes biopsy (2) and cryoglobulinemic vascularitis based on renal biopsy (1).
  • Mesenteric panniculitis is often associated with lymphoma.

  • Genetic Alliance. consumer health - Panniculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316921.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Shen M, Zheng T, Lan Q, Zhang Y, Zahm SH, Wang SS, Holford TR, Leaderer B, Yeager M, Welch R, Kang D, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S, Rothman N: Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet; 2006 Jul;119(6):659-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut.
  • Several hereditary syndromes characterized by defective DNA repair are associated with high risk of non-Hodgkin lymphoma (NHL).
  • SNPs in four genes (ERCC5, ERCC2, WRN, and BRCA1) were associated with altered risk of NHL and diffuse large B-cell lymphoma (DLBCL), the major B cell subtype.
  • In particular, ERCC5 Asp1104His was associated with increased risk of NHL overall (OR: 1.46; 95% CI: 1.13-1.88; P=0.004), DLBCL (OR: 1.44; 95% CI: 0.99-2.09; P=0.058), and also T cell lymphoma.
  • [MeSH-major] DNA Repair / genetics. Genetic Predisposition to Disease. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Connecticut. Female. Humans. Middle Aged. Risk Factors

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicology. 2003 Nov 15;193(1-2):3-34 [14599765.001]
  • [Cites] Lab Invest. 2003 May;83(5):643-54 [12746474.001]
  • [Cites] Am J Med Genet. 2000 Dec 11;95(4):374-80 [11186893.001]
  • [Cites] Epidemiol Rev. 1998;20(2):187-203 [9919438.001]
  • [Cites] Cell Death Differ. 2006 Mar;13(3):478-88 [16167068.001]
  • [Cites] Cornea. 2004 Nov;23(8 Suppl):S42-7 [15448479.001]
  • [Cites] Cytogenet Genome Res. 2004;104(1-4):95-9 [15162020.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Carcinogenesis. 2000 Aug;21(8):1527-30 [10910954.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jan 1;116(1):81-3 [10616539.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):396-411 [11071361.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D528-32 [14681474.001]
  • [Cites] DNA Repair (Amst). 2005 Mar 2;4(3):351-7 [15661658.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):671-5 [12494477.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):22-5 [14657658.001]
  • [Cites] Mol Cell. 2005 Oct 28;20(2):187-98 [16246722.001]
  • [Cites] Mech Ageing Dev. 2005 Nov;126(11):1146-58 [16087220.001]
  • [Cites] Mutat Res. 2005 Sep 4;577(1-2):237-51 [15946710.001]
  • [Cites] Am J Med Genet. 1997 Feb 11;68(4):494-8 [9021029.001]
  • [Cites] DNA Repair (Amst). 2005 Aug 15;4(9):1019-27 [15979950.001]
  • [Cites] Genome Res. 2001 May;11(5):863-74 [11337480.001]
  • [Cites] Am J Hum Genet. 2002 Nov;71(5):1227-34 [12384857.001]
  • [Cites] Cancer Causes Control. 2003 Sep;14(7):687-94 [14575367.001]
  • [Cites] Int J Mol Med. 1998 Jan;1(1):71-6 [9852201.001]
  • [Cites] Hum Cell. 2001 Dec;14(4):305-15 [11925933.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):393-7 [11900225.001]
  • [Cites] EMBO J. 2004 Feb 11;23(3):670-80 [14749735.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14 (10 ):2449-53 [16214931.001]
  • [Cites] Oncogene. 2002 Jun 13;21(26):4176-80 [12037675.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55499-505 [15489508.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):687-96 [11401920.001]
  • [Cites] Carcinogenesis. 2003 Oct;24(10):1677-81 [12869423.001]
  • (PMID = 16738949.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 208900/ 210900/ 251260
  • [Grant] United States / NCI NIH HHS / CA / CA62006; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Germany
  •  go-up   go-down


34. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte (GELA): ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med; 2005 Mar 24;352(12):1197-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
  • BACKGROUND: Chemoradiotherapy is standard treatment for localized aggressive lymphoma.
  • To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone.
  • METHODS: Previously untreated patients less than 61 years old with localized stage I or II aggressive lymphoma and no adverse prognostic factors according to the International Prognostic Index were randomly assigned to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (329 patients) or chemotherapy alone with dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus sequential consolidation (318 patients).
  • In a multivariate analysis, event-free and overall survival rates were affected by treatment group, independently of tumor stage and the presence or absence of bulky disease.
  • CONCLUSIONS: In patients under 61 years of age, chemotherapy with three cycles of ACVBP followed by sequential consolidation is superior to three cycles of CHOP plus radiotherapy for the treatment of low-risk localized lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prednisone / administration & dosage. Survival Analysis. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vindesine / administration & dosage

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2005 Jun 9;352(23):2449-51; author reply 2449-51 [15944432.001]
  • [CommentIn] N Engl J Med. 2005 Mar 24;352(12):1250-2 [15788502.001]
  • [CommentIn] N Engl J Med. 2005 Jun 9;352(23):2449-51; author reply 2449-51 [15948267.001]
  • [CommentIn] N Engl J Med. 2005 Jun 9;352(23):2449-51; author reply 2449-51 [15948268.001]
  • (PMID = 15788496.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; RSA8KO39WH / Vindesine; VB0R961HZT / Prednisone; CHOP protocol; LNH 87 protocol
  •  go-up   go-down


35. Wall RJ, Schnapp LM: Radiation pneumonitis. Respir Care; 2006 Nov;51(11):1255-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Abnormalities, Radiation-Induced. Adult. HIV Seropositivity. Hodgkin Disease. Humans. Male. Washington

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067408.001).
  • [ISSN] 0020-1324
  • [Journal-full-title] Respiratory care
  • [ISO-abbreviation] Respir Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC: Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol; 2006 Oct;17(10):1546-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
  • INTRODUCTION: Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large B-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Cyclophosphamide / adverse effects. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / adverse effects. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prednisone / adverse effects. Recurrence. Salvage Therapy. Survival Analysis. Vincristine / adverse effects


37. Il'in NV, Nikolaeva EN, Smirnova EV, Vinogradova IuN, Ivanova EI, Izotov BM, Shenderova IA: [20-year experience with modified dose fractionation of radiotherapy in primary Hodgkin's disease]. Vopr Onkol; 2008;54(4):529-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [20-year experience with modified dose fractionation of radiotherapy in primary Hodgkin's disease].
  • Significantly lower frequency of relapse, incidence of pulmonitis and pericarditis, leukopenia and thrombocytopenia stage IV and longer recurrence-free survival were reported after acceleration of multifractionation of STD of 1.35Gy was used for treatment of patients with primary Hodgkin's disease, as compared with standard fractionation.
  • [MeSH-major] Dose Fractionation. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Aged. Biomedical Research. Disease-Free Survival. Female. Humans. Incidence. Kaplan-Meier Estimate. Leukopenia / epidemiology. Leukopenia / etiology. Male. Middle Aged. Pericarditis / epidemiology. Pericarditis / etiology. Pneumonia / epidemiology. Pneumonia / etiology. Radiotherapy / adverse effects. Recurrence. Retrospective Studies. Russia / epidemiology. Severity of Illness Index. Thrombocytopenia / epidemiology. Thrombocytopenia / etiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942416.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


38. Mrzljak A, Gasparov S, Kardum-Skelin I, Colic-Cvrlje V, Ostojic-Kolonic S: Febrile cholestatic disease as an initial presentation of nodular lymphocyte-predominant Hodgkin lymphoma. World J Gastroenterol; 2010 Sep 21;16(35):4491-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Febrile cholestatic disease as an initial presentation of nodular lymphocyte-predominant Hodgkin lymphoma.
  • Febrile cholestatic liver disease is an extremely unusual presentation of Hodgkin lymphoma (HL).
  • [MeSH-major] Cholestasis. Fever. Hodgkin Disease / complications. Hodgkin Disease / physiopathology. Lymphocytes / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Mar 15;71(6):2062-71 [8443755.001]
  • [Cites] Am J Gastroenterol. 1992 Sep;87(9):1194-5 [1519580.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):776-83 [10071266.001]
  • [Cites] Lancet. 2006 Mar 25;367(9515):1028 [16564367.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5739-45 [16009944.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1999 Sep;11(9):1055-8 [10503847.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 Mar;16(2):196-201 [18227720.001]
  • [Cites] Acta Oncol. 2008;47(5):962-70 [17906981.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Mar;14(3):323-7 [11953700.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):489-95 [15087668.001]
  • [Cites] Dig Liver Dis. 2004 Oct;36(10):691-3 [15506670.001]
  • [Cites] Cancer. 1971 Nov;28(5):1335-42 [5125679.001]
  • [Cites] Q J Med. 1979 Jan;48(189):137-50 [482587.001]
  • [Cites] J Surg Oncol. 1980;14(2):111-23 [7392635.001]
  • [Cites] J Clin Gastroenterol. 1986 Jun;8(3 Pt 1):304-7 [3734366.001]
  • [Cites] Semin Liver Dis. 1987 Aug;7(3):257-68 [3317862.001]
  • [Cites] N Engl J Med. 1988 Jan 28;318(4):214-9 [3336412.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1303-9 [2769329.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2121-6 [2804900.001]
  • [Cites] Gut. 1991 Aug;32(8):959-62 [1885082.001]
  • [Cites] Ann Hematol. 1996 Jun;72(6):357-60 [8767104.001]
  • (PMID = 20845519.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2941075
  •  go-up   go-down


39. De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, van't Veer MB, Aleman BM, van Leeuwen FE: Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood; 2008 Jan 1;111(1):101-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related risk factors for premature menopause following Hodgkin lymphoma.
  • We conducted a cohort-study among 518 female 5-year Hodgkin lymphoma (HL) survivors, aged 14 to 40 years (median: 25 years) at treatment (1965-1995).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Menopause, Premature
  • [MeSH-minor] Adolescent. Adult. Bleomycin / adverse effects. Combined Modality Therapy. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Mechlorethamine / adverse effects. Medical Records. Multivariate Analysis. Prednisone / adverse effects. Procarbazine / adverse effects. Proportional Hazards Models. Radiotherapy / adverse effects. Risk Factors. Vinblastine / adverse effects. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890454.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; MOPP protocol; VBA protocol
  •  go-up   go-down


40. Liu YH, Zhuang HG, Lin HL, Wu QL, Luo DL, Li L, Luo XL: [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):594-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
  • OBJECTIVE: To study the differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and T-cell/histiocyte-rich B-cell lymphoma (TCRBCL).
  • One case showed a combination of nodules of NLPHL, diffuse areas of TCRBCL and a sheet of large cells of diffuse large B-cell lymphoma (DLBCL) within the same lymph node biopsy specimen.
  • A combination of the morphological characteristics and the reactivity of the background cells for CD57 and TIA-1 seem to reliably discriminate between the entities and should therefore help to increase the interobserver reproducibility of diagnosis in the gray zone around Hodgkin lymphomas.
  • [MeSH-major] Hodgkin Disease / pathology. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD57 / metabolism. Child. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Humans. Immunophenotyping. Male. Middle Aged. Poly(A)-Binding Proteins / metabolism. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243292.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD57; 0 / Poly(A)-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


41. Segura-Ortí E: [Exercise in haemodyalisis patients: a literature systematic review]. Nefrologia; 2010;30(2):236-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Ejercicio en pacientes en hemodiálisis: revisión sistemática de la literatura.
  • Exercise as a therapeutic tool used in End-stage renal disease patients (ESRD) in hemodialysis (HD) is not routinately applied, as it occurs with cardiac or respiratory patients.
  • 1) to systematically review the literature of exercise training on adult HD patients or patients at a pre-HD stage;.
  • 3) to recommend requirements of future research in order to include exercise prescription in the HD patients treatment.
  • Randomized Controlled Trials on aerobic, strength and combined programs for HD patients were selected.
  • Future studies should clarify which out of the three modalities results in higher benefits for HD patients.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Exercise. Exercise Tolerance. Female. Humans. Male. Middle Aged. Oxygen Consumption. Quality of Life. Randomized Controlled Trials as Topic / statistics & numerical data. Research Design. Resistance Training. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098466.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 50
  •  go-up   go-down


42. Iyengar P, Mazloom A, Shihadeh F, Berjawi G, Dabaja B: Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes. Cancer; 2010 Aug 15;116(16):3825-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin lymphoma involving extranodal and nodal head and neck sites: characteristics and outcomes.
  • BACKGROUND: Most Hodgkin lymphoma (HL) patients present with disease in nodal regions.
  • However, in a small subset, disease develops in unique anatomic sites such as the head and neck area.
  • Specifically, 10 of 34 patients had disease in the tonsils, 9 in the nasopharynx, 8 in the thyroid, 3 in the parotid, 2 in the adenoids, and 1 each in Waldeyer's ring and nasal antrum.
  • Median age at diagnosis was 31.5 years, average age at diagnosis was 38 years, and 22 of 34 were male; 23 had stage I or II disease.
  • Twenty-nine of 34 had nodal neck disease at presentation.
  • At last follow-up, 85% were disease-free.
  • CONCLUSIONS: HL of the head and neck is primarily diagnosed as early stage disease of men and of young to middle-aged individuals.
  • The extent to which nodal disease is present in the neck does not alter outcomes when combined modality therapy is offered.
  • Despite the unique anatomic location of these lesions, standard HL protocols work effectively to promote disease-free survival.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Hodgkin Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564093.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Introcaso CE, Kantor J, Porter DL, Junkins-Hopkins JM: Cutaneous Hodgkin's disease. J Am Acad Dermatol; 2008 Feb;58(2):295-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous Hodgkin's disease.
  • Cutaneous Hodgkin's disease is a rare condition that usually occurs late in the course of Hodgkin's lymphoma.
  • This rare condition is thought to have decreased in incidence in recent decades, likely owing to improved treatment of patients with Hodgkin's disease, who are receiving improved chemotherapy and radiation therapy, and the advent of peripheral blood stem cell transplantation.
  • We present the case of a man who developed specific cutaneous Hodgkin's lymphoma 6 months after nonmyeloablative allogenic stem cell transplantation for his recurrent systemic disease.
  • At the time of the cutaneous relapse he had minimal systemic disease.
  • This case illustrates an example of this complication of Hodgkin's disease and stresses the importance of a timely diagnosis to direct appropriate therapy.
  • A review of the literature demonstrates that the patient's lesion morphology and distribution are typical of specific manifestations of cutaneous Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / complications. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Erythema / etiology. Erythema / pathology. Graft vs Tumor Effect. Humans. Male. Recurrence. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222326.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


44. Abboud B, Yazbeck T, Daher R, Chahine G, Ghorra C: Papillary thyroid carcinoma after chemotherapy for Hodgkin's disease. Am Surg; 2010 Nov;76(11):1316-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary thyroid carcinoma after chemotherapy for Hodgkin's disease.
  • [MeSH-major] Carcinoma, Papillary / etiology. Carcinoma, Papillary / surgery. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / surgery. Thyroid Neoplasms / etiology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21140714.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


45. Falagas ME, Rafailidis PI, Kapaskelis A, Peppas G: Pyomyositis associated with hematological malignancy: case report and review of the literature. Int J Infect Dis; 2008 Mar;12(2):120-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The case patient, a 46-year old female, had non-tropical pyomyositis of the iliopsoas and obturator muscles due to Staphylococcus aureus and underlying Hodgkin's disease.
  • Forty-four patients with pyomyositis and an associated hematological malignant disease have been reported in the literature.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Humans. Male. Middle Aged. Multiple Myeloma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Staphylococcus aureus / isolation & purification. Treatment Outcome

  • Genetic Alliance. consumer health - Pyomyositis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17723316.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Number-of-references] 29
  •  go-up   go-down


46. Case DC Jr, Desch CE, Kalman LA, Vongkovit P, Mena RR, Fridman M, Allen B: Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma; 2007 Mar;7(5):354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
  • BACKGROUND: Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or high-grade non-Hodgkin lymphoma but might be difficult in older patients.
  • PATIENTS AND METHODS: This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving R-CHOP with filgrastim.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Drug-Related Side Effects and Adverse Reactions. Female. Filgrastim. Follow-Up Studies. Humans. Male. Maximum Allowable Concentration. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Recombinant Proteins. Risk Factors. Rituximab. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562245.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


47. Jones OM, McCutcheon J, Herieka E, Fozard JB: High-grade lymphoma of the ileoanal pouch in an HIV-positive patient. Colorectal Dis; 2007 Feb;9(2):184-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade lymphoma of the ileoanal pouch in an HIV-positive patient.
  • [MeSH-major] Colonic Pouches / pathology. HIV Seropositivity. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Proctocolectomy, Restorative

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223949.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


48. Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, Gokden M, Spinner RJ: Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. Am J Surg Pathol; 2009 Mar;33(3):325-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With one exception, the tumors affected adults (age range 5 to 69 y, mean 39, median 32).
  • One patient was irradiated for hypothalamic pilocytic astrocytoma and another for cervical Hodgkin disease.
  • [MeSH-minor] Adult. Aged. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065105.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Nemani KL: Finding cancer at home. Am J Manag Care; 2010 Dec;16(12 Suppl HIT):e330-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Attitude of Health Personnel. Hodgkin Disease / epidemiology. Hodgkin Disease / psychology
  • [MeSH-minor] Carcinogens. Cluster Analysis. Electronic Health Records. Environmental Exposure / adverse effects. Female. Humans. New Hampshire. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21322305.001).
  • [ISSN] 1936-2692
  • [Journal-full-title] The American journal of managed care
  • [ISO-abbreviation] Am J Manag Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens
  •  go-up   go-down


50. Hjermstad MJ, Fosså SD, Oldervoll L, Holte H, Jacobsen AB, Loge JH: Fatigue in long-term Hodgkin's Disease survivors: a follow-up study. J Clin Oncol; 2005 Sep 20;23(27):6587-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatigue in long-term Hodgkin's Disease survivors: a follow-up study.
  • PURPOSE: To describe total fatigue (TF) and chronic fatigue (CF) in 476 long-term Hodgkin's disease survivors (HDSs).
  • [MeSH-major] Fatigue / epidemiology. Fatigue / etiology. Hodgkin Disease / complications. Hodgkin Disease / therapy. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Analysis of Variance. Combined Modality Therapy. Fatigue Syndrome, Chronic / epidemiology. Fatigue Syndrome, Chronic / etiology. Female. Follow-Up Studies. Health Surveys. Humans. Male. Middle Aged. Norway / epidemiology. Prevalence. Probability. Severity of Illness Index. Sex Distribution. Sickness Impact Profile. Statistics, Nonparametric. Surveys and Questionnaires. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170166.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J: Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant; 2009 Aug;15(8):919-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
  • Incidence of grade II-IV acute graft-versus-host disease (aGVHD) in nonmyeloablative (NMA) transplant recipients remains high.
  • Most common diagnoses included MM (N = 62), non-Hodgkin lymphoma (NHL, N = 46), and acute leukemia (N = 10).
  • Following NMA transplant, disease-free survival (DFS) was highest in recipients with follicular NHL (79.8%: 95% CI: 57.6-91.2) and lowest in large cell NHLs (34.3%: 95% CI: 1.6-75.9).
  • [MeSH-major] Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation / adverse effects. Mycophenolic Acid / analogs & derivatives. Tacrolimus / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemoprevention / methods. Cohort Studies. Drug Therapy, Combination. Female. HLA Antigens. Histocompatibility. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Male. Middle Aged. Outpatients. Survival Analysis. Transplantation Conditioning / methods. Young Adult

  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19589481.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Immunosuppressive Agents; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


52. Kumar R, Sidhu H, Mistry R, Shet T: Primary pulmonary Hodgkin's lymphoma: a rare pitfall in transthoracic fine needle aspiration cytology. Diagn Cytopathol; 2008 Sep;36(9):666-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary Hodgkin's lymphoma: a rare pitfall in transthoracic fine needle aspiration cytology.
  • Primary pulmonary Hodgkin's lymphoma (PPHL) is extremely rare.
  • At an extranodal location such as the lung this lymphoma is likely to be confused with the more commonly occurring carcinomas at this site.
  • Two years later, the patient developed enlarged nodes which were diagnosed as Hodgkin's lymphoma, and a review of prior lung tumor confirmed the diagnosis of PPHL.
  • [MeSH-major] Diagnostic Errors. Hodgkin Disease / diagnosis. Hodgkin Disease / pathology. Lung / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677750.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Dögel D, Beuing O, Koenigsmann M, Diete S: [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports]. Fortschr Neurol Psychiatr; 2008 Jan;76(1):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic limbic encephalitis resulting from non-Hodgkin-lymphoma: two case reports].
  • [Transliterated title] Paraneoplastische Limbische Enzephalitis als Erstmanifestation eines malignen Non Hodgkin Lymphoms.
  • Paraneoplastic limbic encephalitis (PLE) is a rare disease that is probably caused by an immunological reaction against CNS-structures.
  • Besides treatment of the underlying neoplastic disease, there is no generally applicable evidence-based treatment.
  • PLE is most frequently associated with certain carcinomas, but its occurrence with Hodgkin lymphoma has also been recognized.
  • Association with non-Hodgkin lymphoma has only been occasionally reported in single cases.
  • We report two additional patients, in whom malignant non-Hodgkin lymphomas of the B- and T-cell lines were detected.
  • [MeSH-major] Limbic Encephalitis / etiology. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Electroencephalography. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Limbic encephalitis.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18189222.001).
  • [ISSN] 0720-4299
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


54. Retter A, Ardeshna KM, O'Driscoll A: Cardiac tamponade in Hodgkin lymphoma. Br J Haematol; 2007 Jul;138(1):2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac tamponade in Hodgkin lymphoma.
  • [MeSH-major] Cardiac Tamponade / etiology. Hodgkin Disease / complications. Neoplasm Recurrence, Local / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Heart / radiography. Humans. Pericardial Effusion / etiology. Pericardial Effusion / radiography. Pericardial Effusion / therapy. Salvage Therapy. Stem Cell Transplantation. Tomography, X-Ray Computed. Transplantation, Homologous


55. Blum KA, Jung SH, Johnson JL, Lin TS, Hsi ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL, Cancer and Leukemia Group B: Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol; 2010 Nov;21(11):2246-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
  • BACKGROUND: Based on in vitro synergistic cytotoxicity when anti-CD30 antibodies are combined with gemcitabine, the Cancer and Leukemia Group B conducted a double-blind, randomized, phase II trial of SGN-30 with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) in patients with relapsed Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Arthritis Rheum. 2008 Apr;58(4):1165-74 [18383361.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):96-100 [11823707.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3736-42 [12097283.001]
  • [Cites] Invest New Drugs. 2002 Aug;20(3):311-5 [12201493.001]
  • [Cites] Thyroid. 2003 Mar;13(3):259-63 [12729474.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):978-82 [12942565.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] J Immunother. 2004 Sep-Oct;27(5):347-53 [15314543.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2635-42 [15226177.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2083-7 [2566368.001]
  • [Cites] Arch Pathol Lab Med. 1992 Nov;116(11):1197-201 [1332642.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3378-404 [7780126.001]
  • [Cites] Cell. 1996 Feb 23;84(4):551-62 [8598042.001]
  • [Cites] Nature. 1999 Mar 25;398(6725):341-4 [10192335.001]
  • [Cites] Immunol Rev. 1999 Jun;169:23-9 [10450505.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1648-55 [16049514.001]
  • [Cites] Respir Res. 2005;6:81 [16042790.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jan;117(1):204-11 [16387607.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):353-60 [16329112.001]
  • [Cites] J Heart Lung Transplant. 2006 Apr;25(4):416-9 [16563971.001]
  • [Cites] Immunology. 2006 Jun;118(2):143-52 [16771849.001]
  • [Cites] Transplantation. 2006 Dec 27;82(12):1596-601 [17198242.001]
  • [Cites] Haematologica. 2007 Jan;92(1):35-41 [17229633.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]
  • [Cites] Clin Exp Immunol. 2007 Mar;147(3):472-82 [17302896.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2225-33 [17068147.001]
  • [Cites] J Thorac Oncol. 2006 Jun;1(5):434-40 [17409896.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):1071-9 [17426059.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):916-9 [17597477.001]
  • [Cites] Transpl Immunol. 2008 Jan;18(3):260-3 [18047935.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4370-2 [17909075.001]
  • [Cites] Eur J Dermatol. 2008 Jan-Feb;18(1):41-9 [18086588.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1848-54 [18079362.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • (PMID = 20423913.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA07968
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / FCGR3A protein, human; 0 / Receptors, IgG; 0 / SGN-30 monoclonal antibody; 0 / liposomal doxorubicin; 0W860991D6 / Deoxycytidine; 30IQX730WE / Polyethylene Glycols; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2962257
  •  go-up   go-down


56. Herling M, Rassidakis GZ, Vassilakopoulos TP, Medeiros LJ, Sarris AH: Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. Blood; 2006 Feb 1;107(3):1240; author reply 1241
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Gene Expression Regulation, Viral. Hodgkin Disease / metabolism. Viral Matrix Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • (PMID = 16434497.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


57. Vural F, Akad Soyer N, Özen P, Dönmez A, Ocakçı S, Saydam G, Çağırgan S, Tombuloğlu M: Non-Hodgkin's lymphoma with bone involvement: a single center experience with 18 patients. Turk J Haematol; 2010 Mar 5;27(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma with bone involvement: a single center experience with 18 patients.
  • [Transliterated title] Kemik tutulumlu Hodgkin dışı lenfoma: Onsekiz hasta ile tek merkez deneyimi.
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) of bone is a rare entity.
  • The most common histological subtype is diffuse large B cell lymphoma (DLBCL).
  • Other histological subtypes were anaplastic large cell lymphoma (11.1%), Burkitt-like lymphoma (5.6%) and marginal zone lymphoma (5.6%).
  • CONCLUSION: The treatment of bone lymphoma can be planned according to the stage and location of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265795.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


58. Crom DB, Hinds PS, Gattuso JS, Tyc V, Hudson MM: Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach. Oncol Nurs Forum; 2005 Nov;32(6):1131-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach.
  • PURPOSE/OBJECTIVES: To learn from female survivors of Hodgkin disease about their perceptions of their current health status and future health risks, self-care practices to prevent or diminish health risks, and what kind of breast health program could benefit them, including the most effective methods and optimal times for learning about breast health.
  • SAMPLE: 1 African American and 19 Caucasian female survivors of Hodgkin disease aged 16-26 years, diagnosed at least two years before the start of the study, and treated with mantle radiation therapy.
  • Effective methods identified for learning about breast health included having access to other survivors, being respected as an adult, and having one-on-one staff teaching and peer support.
  • [MeSH-major] Breast Neoplasms / prevention & control. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / prevention & control. Neoplasms, Second Primary / prevention & control. Patient Education as Topic / methods. Survivors
  • [MeSH-minor] Adolescent. Adult. Female. Focus Groups. Health Knowledge, Attitudes, Practice. Humans. Models, Theoretical. Patient Participation / methods. Program Development / methods. Radiotherapy / adverse effects. Research Design. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270109.001).
  • [ISSN] 1538-0688
  • [Journal-full-title] Oncology nursing forum
  • [ISO-abbreviation] Oncol Nurs Forum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


59. Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V: Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma; 2005 Jun;46(6):861-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
  • High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma.
  • Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy could benefit from HDT.
  • We retrospectively investigated the prognostic value of the widely used age-adjusted International Prognostic Index (AA-IPI) calculated at the time of relapse (35 patients) or just before second-line salvage therapy for primary refractory disease (5 patients).
  • Thirty-six patients had diffuse large B-cell lymphoma.
  • Ten patients had an IPI >1, 16 had relapsed early (<6 months after first-line therapy) or disease was refractory to first-line therapy (5 of the 16 patients).
  • Overall survival was not statistically different in patients with refractory disease or in those who relapsed early compared with late failures (>6 months after first-line chemotherapy) (P=1), but the AA-IPI >1 was associated with a poor outcome (P=0.03).
  • In conclusion, the AA-IPI could have a prognostic value in patients with chemosensitive recurrent lymphoma treated with BEAM HDT.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Male. Medical Oncology / standards. Melphalan / therapeutic use. Middle Aged. Prednisolone / therapeutic use. Prognosis. Recurrence. Remission Induction. Transplantation, Autologous. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019530.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen; VAP-cyclo protocol
  •  go-up   go-down


60. Mulnix JW: Case one: Patient autonomy and the freedom to act against one's self-interest. Clin Lab Sci; 2008;21(2):114-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 16-year-old Hodgkin lymphoma patient refuses to have his blood specimen drawn, thus canceling his scheduled oncologic treatment.
  • As a 16-year-old, he has no legal standing as an adult.
  • [MeSH-major] Freedom. Hodgkin Disease / drug therapy. Personal Autonomy. Treatment Refusal / ethics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507307.001).
  • [ISSN] 0894-959X
  • [Journal-full-title] Clinical laboratory science : journal of the American Society for Medical Technology
  • [ISO-abbreviation] Clin Lab Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Novik KL, Spinelli JJ, Macarthur AC, Shumansky K, Sipahimalani P, Leach S, Lai A, Connors JM, Gascoyne RD, Gallagher RP, Brooks-Wilson AR: Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev; 2007 Jun;16(6):1098-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) comprises a group of lymphoid tumors that have in common somatic translocations.
  • H2afx is a dosage-dependent gene that protects against B-cell lymphomas in mice, making its human orthologue an ideal candidate gene for susceptibility to lymphoma.
  • We find a strong association of this SNP with the follicular lymphoma subtype of NHL (AA genotype: OR, 0.40; P = 0.004) and with mantle cell lymphoma (AA genotype: OR, 0.20; P = 0.01) that remains significant after adjustment for the false discovery rate, but not with diffuse large B-cell lymphoma.
  • [MeSH-major] Genetic Predisposition to Disease. Histones / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Animals. Base Sequence. Biological Evolution. Case-Control Studies. Female. Genotype. Humans. Linkage Disequilibrium. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction. Risk Factors. Sequence Homology, Nucleic Acid

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548670.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones
  •  go-up   go-down


62. Abdulkader I, Fraga M, González-Quintela A, Caparrini A, Bello JL, Galbán C, Varo E, Diaz-Mediavilla J, Forteza J: Prolonged survival after liver transplantation for Hodgkin's disease-induced fulminant liver failure. Hepatogastroenterology; 2005 Jan-Feb;52(61):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival after liver transplantation for Hodgkin's disease-induced fulminant liver failure.
  • A 30-year-old male with a past history of nodular lymphocyte predominance Hodgkin's disease in apparent complete remission for two years received a liver transplantation because of fulminant liver failure.
  • Histopathological examination of the explanted liver showed massive infiltration by Hodgkin's disease.
  • In spite of a nodal recurrence of Hodgkin's disease, the patient is alive and in excellent general condition six years after liver transplantation.
  • [MeSH-major] Hodgkin Disease / complications. Liver Failure, Acute / etiology. Liver Failure, Acute / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Humans. Male. Survivors. Treatment Outcome


63. Strianese D, Tranfa F, Finelli M, De Renzo A, Staibano S, Schiemer R, Cardone D, Pacelli R, Perna F, Mascolo M, De Rosa G, Bonavolontà G: Hepatitis C virus infection in ocular adnexal lymphomas. Arch Ophthalmol; 2010 Oct;128(10):1295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the influence of hepatitis C virus (HCV) infection on disease appearance and outcome of ocular adnexal non-Hodgkin lymphoma (ONHL).
  • MAIN OUTCOME MEASURES: Prevalence of HCV infection, staging to evaluate the extent of disease at the onset, and clinical outcome data on overall and disease-free survival.
  • Seropositivity for HCV infection was significantly associated with extraorbital lymphoma at the onset (P = .006).
  • High prevalence of mucosa-associated lymphoid tissue disease (79.8%) was registered.
  • Protocol therapy included radiotherapy and chemotherapy, depending on the stage of the disease.
  • A total of 23.6% of patients with HCV-seronegative status and 21.7% of those with HCV-seropositive status experienced relapse of the lymphomatous disease.
  • No significant differences in the 5-year overall survival and disease-free survival between the 2 groups were observed.
  • Infection with HCV may influence the initial appearance of ONHL because it is associated with more widespread disease at the onset.
  • However, the overall and disease-free survival of the infected patients are not statistically different than that of patients who are not infected.
  • [MeSH-major] Eye Infections, Viral / virology. Eye Neoplasms / virology. Hepatitis C / virology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Conjunctival Neoplasms / mortality. Conjunctival Neoplasms / pathology. Conjunctival Neoplasms / therapy. Conjunctival Neoplasms / virology. Disease-Free Survival. Eyelid Neoplasms / mortality. Eyelid Neoplasms / pathology. Eyelid Neoplasms / therapy. Eyelid Neoplasms / virology. Female. Humans. Lacrimal Apparatus Diseases / mortality. Lacrimal Apparatus Diseases / pathology. Lacrimal Apparatus Diseases / therapy. Lacrimal Apparatus Diseases / virology. Male. Middle Aged. Neoplasm Staging. Orbital Neoplasms / mortality. Orbital Neoplasms / pathology. Orbital Neoplasms / therapy. Orbital Neoplasms / virology. Prevalence. Radiotherapy. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20937999.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


64. Kanaev SV, Girshovich MM, Golovanov SG, Gershanovich ML: [Is irradiation of intact ileoinguinal lymph nodes necessary in radiochemotherapy for stage-III Hodgkin's disease?]. Vopr Onkol; 2007;53(4):453-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is irradiation of intact ileoinguinal lymph nodes necessary in radiochemotherapy for stage-III Hodgkin's disease?].
  • Data are presented on radiochemotherapy (1-4 cycles of combined therapy+total (TI) or subtotal (STI) irradiation of lymph nodes) given to 120 patients, with stage III Hodgkin's disease, whose ileoinguinal lymph nodes were intact.
  • Analysis of overall survival of patients with stage III Hodgkin's disease showed that 87% of STI patients survived for 10-years as compared with 73% in TI (p=0.07).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Lymph Nodes / radiation effects
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Groin. Humans. Ileum. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969410.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


65. Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF: Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Radiology; 2007 Jul;244(1):257-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
  • PURPOSE: To retrospectively determine the sensitivity and specificity of co-registered fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with Hodgkin lymphoma after first-line therapy, with use of clinical follow-up or biopsy results as the reference standard.
  • Between May 2001 and July 2005, the data for all patients (n=66) at the authors' institution with proved Hodgkin lymphoma after first-line therapy were retrospectively reviewed.
  • All patients with negative PET/CT scans at follow-up were evaluated for disease-free survival.
  • Recurrence of Hodgkin lymphoma was confirmed with biopsy in 23 of the 27 patients.
  • Thirty-nine patients (mean age, 36.7 years +/- 10.8) did not have FDG-avid lesions and remained free of disease after a mean clinical follow-up of 26.2 months (+/-12.5) (specificity, 91% [39 of 43 patients]; sensitivity, 100% [23 of 23 patients]).
  • The presence of bulky disease (>5 cm) after the end of treatment was a significant predictor of recurrent disease (P<.05).
  • CONCLUSION: The authors conclude that FDG PET/CT can help exclude persistent and/or recurrent Hodgkin lymphoma after first-line therapy.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radiography. Hodgkin Disease / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Recurrence. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2007.
  • (PMID = 17581905.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


66. Passam FH, Sfiridaki A, Pappa C, Kyriakou D, Petreli E, Roussou PA, Alexandrakis MG: Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol; 2008 Feb;30(1):17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment.
  • Increased angiogenesis has been shown to be a feature of non-Hodgkin lymphomas (NHL).
  • In the current study, the pretreatment levels of circulating molecules related to angiogenesis were determined in 49 B-cell NHL patients and correlated with histological grade, disease stage and prognostic score.
  • There was no association with disease stage or the International Prognostic Score.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interleukins / blood. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / drug therapy. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Prognosis. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190463.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


67. G S, Garg A, S T: Iatrogenic left main coronary artery stenosis. Indian Heart J; 2007 Jul-Aug;59(4):386
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aortic Valve / surgery. Coronary Angiography. Coronary Artery Bypass. Female. Heart Valve Prosthesis Implantation / adverse effects. Hodgkin Disease / radiotherapy. Humans. Iatrogenic Disease. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126952.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


68. Karantanis D, O'eill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA: 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun; 2007 Nov;28(11):834-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
  • OBJECTIVE: To determine the value of F-FDG PET/CT in the different manifestations of primary central nervous system lymphoma (PCNSL) in HIV-negative patients.
  • PET/CT results were characterized as true positive or negative and false positive or negative according to the status of the disease, which was determined after the evaluation of biopsies, laboratory, clinical and imaging examinations, and follow-up.
  • For intracerebral disease, PET/CT was true positive in 13 cases, true negative in 27 and false negative in two.
  • For disease involving spinal cord and/or nerves, PET/CT was true positive in four cases, true negative in 37 and false negative in one.
  • For ocular disease, PET was true positive in only one case and false negative in four.
  • The sensitivity of PET/CT in detecting active disease in the brain was 87% (13/15), in the spine/nerves 80% (4/5), and in the eyes only 20% (1/5).
  • CONCLUSION: PET/CT seems to be sensitive for the detection of viable intracerebral as well as for spinal and peripheral nerve disease, but not for the detection of ocular involvement.
  • [MeSH-major] Central Nervous System Neoplasms / radionuclide imaging. Lymphoma, Non-Hodgkin / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cohort Studies. Female. Fluorodeoxyglucose F18. HIV Seronegativity. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Positron-Emission Tomography. Radiopharmaceuticals. Retrospective Studies. Rituximab

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17901765.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


69. Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH, Kerstann KF, Wheeler W, Hemminki K, Linet MS, Goldin LR: Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst; 2006 Sep 20;98(18):1321-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.
  • BACKGROUND: Personal history of autoimmune diseases is consistently associated with increased risk of non-Hodgkin lymphoma.
  • In contrast, there are limited data on risk of Hodgkin lymphoma following autoimmune diseases and almost no data addressing whether there is a familial association between the conditions.
  • METHODS: Using population-based linked registry data from Sweden and Denmark, 32 separate autoimmune and related conditions were identified from hospital diagnoses in 7476 case subjects with Hodgkin lymphoma, 18,573 matched control subjects, and more than 86,000 first-degree relatives of case and control subjects.
  • RESULTS: We found statistically significantly increased risks of Hodgkin lymphoma associated with personal histories of several autoimmune conditions, including rheumatoid arthritis (OR = 2.7, 95% CI = 1.9 to 4.0), systemic lupus erythematosus (OR = 5.8, 95% CI = 2.2 to 15.1), sarcoidosis (OR = 14.1, 95% CI = 5.4 to 36.8), and immune thrombocytopenic purpura (OR = infinity, P = .002).
  • A statistically significant increase in risk of Hodgkin lymphoma was associated with family histories of sarcoidosis (OR = 1.8, 95% CI = 1.01 to 3.1) and ulcerative colitis (OR = 1.6, 95% CI = 1.02 to 2.6).
  • CONCLUSIONS: Personal or family history of certain autoimmune conditions was strongly associated with increased risk of Hodgkin lymphoma.
  • The association between both personal and family histories of sarcoidosis and a statistically significantly increased risk of Hodgkin lymphoma suggests shared susceptibility for these conditions.
  • [MeSH-major] Autoimmune Diseases / complications. Autoimmune Diseases / epidemiology. Hodgkin Disease / epidemiology. Hodgkin Disease / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Arthritis, Rheumatoid / complications. Arthritis, Rheumatoid / epidemiology. Case-Control Studies. Colitis, Ulcerative / complications. Colitis, Ulcerative / epidemiology. Denmark / epidemiology. Disease Susceptibility. Female. Humans. Logistic Models. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / epidemiology. Male. Middle Aged. Odds Ratio. Purpura, Thrombocytopenic, Idiopathic / complications. Purpura, Thrombocytopenic, Idiopathic / epidemiology. Registries. Risk Assessment. Risk Factors. Sarcoidosis / complications. Sarcoidosis / epidemiology. Sweden / epidemiology

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985251.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


70. Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L: Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol; 2007 Mar;78(3):206-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
  • BACKGROUND: Early-stage Hodgkin lymphoma (HL) has excellent survival rates but carries a high risk of late treatment-related adverse effects.
  • Modern, individualised therapeutic strategies require an accurate determination of the extent of the disease.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / diagnosis. Hodgkin Disease / radiotherapy. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253974.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Kilani B, Ammari L, Tiouiri H, Kanoun F, Ben Romdhane K, Ben Chaabane T: [Transverse myelitis revealing Hodgkin disease]. Presse Med; 2006 Apr;35(4 Pt 1):615-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transverse myelitis revealing Hodgkin disease].
  • [Transliterated title] Myélite transverse révélant une maladie de Hodgkin.
  • INTRODUCTION: Neurological complications during Hodgkin disease are rare and sometimes difficult to diagnose.
  • DISCUSSION: The variable neurological events observed during Hodgkin disease may serve to reveal this disease.
  • [MeSH-major] Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Myelitis, Transverse / complications. Myelitis, Transverse / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Myelitis.
  • Genetic Alliance. consumer health - Transverse myelitis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614604.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


72. Glimelius I, Edström A, Fischer M, Nilsson G, Sundström C, Molin D, Amini RM, Enblad G: Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia; 2005 Dec;19(12):2360-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis and mast cells in Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Mast Cells / pathology. Neovascularization, Pathologic / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Humans. Immunohistochemistry. Lymph Nodes / pathology. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224482.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


73. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A: Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A; 2005 Aug 9;102(32):11563-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
  • Misfolded neuronal proteins have been identified in a number of neurodegenerative disorders and have been implicated in the pathogenesis of diseases that include Alzheimer's disease, Parkinson's disease, prion-based dementia, Huntington's disease (HD), and other polyglutamine diseases.
  • Although underlying mechanisms remain the subject of ongoing research, it is clear that aberrant processing, protein degradation, and aggregate formation or spurious protein association of the abnormal neuronal proteins may be critical factors in disease progression.
  • We have modified an approach with intracellularly expressed single-chain Fv (sFv) antibodies (intrabodies) that bind with unique HD protein epitopes.
  • In cell and tissue culture models of HD, anti-N-terminal huntingtin intrabodies (C4 sFv) reduce aggregation and cellular toxicity.
  • Here, we present the crucial experiment of intrabody-mediated in vivo suppression of neuropathology, using a Drosophila model of HD.
  • In the presence of the C4 sFv intrabody, the proportion of HD flies surviving to adulthood increases from 23% to 100%, and the mean and maximum lifespan of adult HD flies is significantly prolonged.
  • [MeSH-major] Huntington Disease / pathology. Huntington Disease / therapy. Immunoglobulin Fragments / therapeutic use. Immunotherapy / methods. Lymphokines / immunology. Protein Engineering / methods. Sialoglycoproteins / immunology

  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2001 Jan;3(1):113-21 [11162318.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):101-6 [11081516.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):739-43 [11607033.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1002-7 [11792860.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):367-76 [11925563.001]
  • [Cites] Trends Genet. 2002 Apr;18(4):202-9 [11932021.001]
  • [Cites] Trends Genet. 2002 Sep;18(9):463-71 [12175807.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):855-64 [12372281.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41032-7 [12171927.001]
  • [Cites] Nature. 2003 Jan 23;421(6921):373-9 [12540902.001]
  • [Cites] Nat Biotechnol. 2003 Feb;21(2):163-70 [12536217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2041-6 [12576549.001]
  • [Cites] Nat Rev Genet. 2003 Mar;4(3):181-94 [12610523.001]
  • [Cites] Science. 2003 Apr 18;300(5618):486-9 [12702875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5950-5 [12730384.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1253-9 [12761040.001]
  • [Cites] Mol Ther. 2003 Sep;8(3):355-66 [12946308.001]
  • [Cites] Annu Rev Neurosci. 2003;26:627-56 [12704223.001]
  • [Cites] Neuron. 2003 Sep 25;40(1):25-40 [14527431.001]
  • [Cites] Neuron. 2003 Nov 13;40(4):685-94 [14622574.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):141-5 [14969746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3224-9 [14978262.001]
  • [Cites] Biochemistry. 2004 Mar 16;43(10):2871-8 [15005622.001]
  • [Cites] Nat Rev Neurosci. 2004 May;5(5):373-84 [15100720.001]
  • [Cites] Bioessays. 2004 May;26(5):485-96 [15112229.001]
  • [Cites] FASEB J. 2004 May;18(7):923-5 [15001566.001]
  • [Cites] Nat Genet. 2004 Jun;36(6):585-95 [15146184.001]
  • [Cites] Hum Mol Genet. 2004 Jul 1;13(13):1389-405 [15115766.001]
  • [Cites] Curr Mol Med. 2004 Aug;4(5):519-28 [15267223.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S2-9 [15272266.001]
  • [Cites] Nat Med. 2004 Jul;10 Suppl:S10-7 [15272267.001]
  • [Cites] J Mol Biol. 2004 Sep 17;342(3):901-12 [15342245.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Cell. 1993 Mar 26;72(6):971-83 [8458085.001]
  • [Cites] Development. 1993 Jun;118(2):401-15 [8223268.001]
  • [Cites] Cell. 1996 Nov 1;87(3):493-506 [8898202.001]
  • [Cites] Adv Protein Chem. 1996;49:329-450 [8908302.001]
  • [Cites] Cell. 1997 Aug 8;90(3):537-48 [9267033.001]
  • [Cites] Science. 1997 Sep 26;277(5334):1990-3 [9302293.001]
  • [Cites] Neuron. 1998 Sep;21(3):633-42 [9768849.001]
  • [Cites] J Neurosci. 1999 Apr 1;19(7):2522-34 [10087066.001]
  • [Cites] J Exp Biol. 1999 Nov;202(Pt 21):3037-48 [10518485.001]
  • [Cites] Curr Opin Mol Ther. 2004 Oct;6(5):482-90 [15537049.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1023-31 [15564134.001]
  • [Cites] Hum Gene Ther. 2004 Nov;15(11):1131-54 [15610613.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17616-21 [15598740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3777-81 [15716359.001]
  • [Cites] Neurobiol Dis. 2005 Jun-Jul;19(1-2):47-56 [15837560.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):425-8 [10581028.001]
  • [Cites] Hum Mol Genet. 2000 Jan 1;9(1):13-25 [10587574.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1837-40 [10710314.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3081-7 [10955787.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9 [11296304.001]
  • (PMID = 16061794.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Fv protein, human; 0 / HTT protein, human; 0 / Immunoglobulin Fragments; 0 / Lymphokines; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Sialoglycoproteins
  • [Other-IDs] NLM/ PMC1183604
  •  go-up   go-down


74. Omoti CE, Halim NK: Adult malignant lymphomas in University of Benin Teaching Hospital, Benin City, Nigeria--incidence and survival. Niger J Clin Pract; 2007 Mar;10(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult malignant lymphomas in University of Benin Teaching Hospital, Benin City, Nigeria--incidence and survival.
  • We aim to determine the incidence and survival of the lymphoma patients in the Niger Delta region of Nigeria.
  • STUDY DESIGN: A study of 205 cases of lymphoma patients from 1993 to 2003.
  • Non-Hodgkin's Lymphoma (NHL) was the most frequent (83%) while Hodgkin's Lymphoma (HL) had an incidence of 17%.
  • Also, the mean Erythrocyte sedimentation rate (ESR) for lymphoma patients alive at lyear was significantly lower than those that died within 1 year (P=0.0001).
  • CONCLUSION: We conclude that NHL was the most common of the lymphoma seen in young adulthood in the Niger Delta region of Nigeria.
  • [MeSH-major] Hodgkin Disease / epidemiology. Lymphoma / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Hospitals, University. Humans. Incidence. Male. Middle Aged. Nigeria / epidemiology. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668708.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


75. Higashi M, Ieiri S, Teshiba R, Saeki I, Esumi G, Taguchi T: Hirschsprung's disease patients diagnosed at over 15 years of age: an analysis of a Japanese nationwide survey. Pediatr Surg Int; 2009 Nov;25(11):945-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hirschsprung's disease patients diagnosed at over 15 years of age: an analysis of a Japanese nationwide survey.
  • PURPOSE: Hirschsprung's disease (HD) is usually diagnosed in patients who are under 1 year of age, however, there are still several reports of adult HD cases.
  • We herein analyzed the data of HD patients collected over 30 years according to a nationwide survey in Japan.
  • METHODS: The data of HD patients over 15 years of age were thus selected in three phases, namely from 1978 to 1982, from 1988 to 1992, and from 1998 to 2002.
  • CONCLUSIONS: Twenty-seven HD patients diagnosed over 15 years of age were analyzed.
  • However, further attention is still required in adult patients who are present with persistent intestinal obstruction of unknown etiology.
  • [MeSH-major] Hirschsprung Disease / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Japan. Male. Middle Aged. Surveys and Questionnaires. Young Adult

  • Genetic Alliance. consumer health - Hirschsprung's disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2005 Jan;40(1):197-201; discussion 201-2 [15868585.001]
  • [Cites] J Nippon Med Sch. 2005 Apr;72(2):113-20 [15940019.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 May;42(5):496-505 [16707970.001]
  • [Cites] J Am Coll Surg. 1998 Dec;187(6):577-83 [9849729.001]
  • (PMID = 19690873.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M: FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer; 2006 Dec 1;107(11):2678-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
  • The objective of this study was to determine the predictive value of FDG-PET as an early response indicator after 1 cycle of chemotherapy for progression-free survival (PFS) in diffuse large cell lymphoma (DLCL) and classic Hodgkin disease (HD).
  • Fourteen of 16 PET-positive patients after 1 cycle had refractory disease or relapsed (median PFS, 5.5 months).
  • CONCLUSIONS: FDG-PET had a high prognostic value after 1 cycle of chemotherapy, thus it can be a valid alternative for posttreatment evaluation of DLCL and HD and may offer the potential for change in treatment paradigms.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fluorodeoxyglucose F18. Hodgkin Disease / drug therapy. Hodgkin Disease / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Iodine Radioisotopes. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Predictive Value of Tests. Prednisone / administration & dosage. Retrospective Studies. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17063502.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


77. Khan H, Pervez S: Coexistence of caseating granulomas with Hodgkin's lymphoma: a diagnostic and clinical dilemma. J Coll Physicians Surg Pak; 2006 Aug;16(8):540-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of caseating granulomas with Hodgkin's lymphoma: a diagnostic and clinical dilemma.
  • Hodgkin's lymphoma (HL) is a neoplasm of the B lymphocytes.
  • A series of cases of Hodgkin's lymphoma is reported in which the biopsy specimens from different parts of the body portrayed caseating granulomatous lesions.
  • [MeSH-major] Hodgkin Disease / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899186.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


78. White JM, Devereux S, Pagliuca A, Salisbury JR, du Vivier AW, Creamer D: Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha. Br J Dermatol; 2006 Sep;155(3):621-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon-alpha.
  • Graft-versus-host disease (GvHD) is a common sequel to allogeneic bone marrow transplants, which may be accompanied by desirable graft-versus-tumour effects.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Graft vs Host Disease / etiology. Interferon-alpha / adverse effects. Lymphocyte Transfusion / adverse effects. Scleroderma, Localized / etiology
  • [MeSH-minor] Adult. Drug Eruptions / etiology. Drug Eruptions / pathology. Hodgkin Disease / therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16911292.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


79. Das DK: Nucleolar positivity for CD20: a diagnostic aid in neoplasms of T-cell lineage? Acta Cytol; 2005 Jul-Aug;49(4):365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: During a period of 5 years (1998-2002), 125 lymphoma cases consisting of 78 non-Hodgkin's lymphoma (NHL), 38 Hodgkin's disease (HD) and 9 NHL/HD were diagnosed by fine needle aspiration (FNA) cytology.
  • Twenty-five were successfully stained; of these, 3, consisting of 2 lymphoblastic lymphomas and 1 large cell lymphoma, showed a positive reaction.
  • CD20 staining performed on 1 of these lymphoblastic lymphomas and the large cell lymphoma showed a diffuse cytoplasmic reaction, respectively, in 2% and 0% only but positive staining of the nucleoli in 96% and 84% of cells, respectively.
  • Another lymphoblastic lymphoma case, which did not have an adequate number of CD3-positive cells to label it as of T-cell lineage also showed CD20 positive nucleoli in 60% of cells and a diffuse cytoplasmic reaction for CD 20 in 5% of cells.
  • [MeSH-major] Antigens, CD20 / metabolism. Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / pathology. T-Lymphocytes / pathology
  • [MeSH-minor] Adult. Antigens, CD3 / metabolism. Biopsy, Fine-Needle. Cell Lineage. Cell Nucleolus / metabolism. Cell Nucleolus / pathology. Child. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16124163.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


80. Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P: Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Jul;47(7):1306-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
  • With currently available combination chemotherapy regimens, the outcome of the patients newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high' and 'high-intermediate' risk groups according to the international prognostic index (IPI) is still unsatisfactory and a more innovative therapy is urgently required to improve the survival of the patients.
  • The purpose of this study was to compare the efficacy of rituximab given in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and ESHAP (etoposide, methylprednisolone, high-dose Ara-C, cisplatin) vs CHOP-ESHAP and upfront high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) vs standard CHOP in patients aged < or = 65 years old newly diagnosed with 'high' and 'high-intermediate' risk aggressive lymphoma enrolled onto two consecutive treatment trials at the institute.
  • Significant increases in failure-free survival (FFS) and disease-free survival (DFS) (61% and 96%), compared with CHOP-ESHAP-HDT (34% and 90%) and CHOP (16% and 44%; p = 0.002 and p < 0.001, respectively) were observed.
  • It is concluded that rituximab-ESHAP-CHOP is superior over standard CHOP and fares comparably to upfront HDT/ASCT in previously untreated patients with aggressive lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Prednisone / administration & dosage. Proportional Hazards Models. Rituximab. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923561.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; CHOP protocol; ESAP protocol
  •  go-up   go-down


81. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F, International Extranodal Lymphoma Study Group (IELSG): High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet; 2009 Oct 31;374(9700):1512-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
  • We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma.
  • 79 patients with non-Hodgkin lymphoma exclusively localised into the CNS, cranial nerves, or eyes, aged 18-75 years, and with Eastern Cooperative Oncology Group performance status of 3 or lower and measurable disease were centrally randomly assigned by computer to receive four courses of either methotrexate 3.5 g/m(2) on day 1 (n=40) or methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice a day on days 2-3 (n=39).
  • INTERPRETATION: In patients aged 75 years and younger with primary CNS lymphoma, the addition of high-dose cytarabine to high-dose methotrexate provides improved outcome with acceptable toxicity compared with high-dose methotrexate alone.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / drug therapy. Cytarabine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Cranial Irradiation / methods. Drug Administration Schedule. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Logistic Models. Middle Aged. Proportional Hazards Models. Remission Induction. Treatment Outcome


82. Tarabar O, Tukić L, Stamatović D, Balint B, Elez M, Ostojić G, Tatomirović Z, Marjanović S: [Autologous stem cell transplantation in the treatment of Hodgkin's disease]. Vojnosanit Pregl; 2009 Jul;66(7):571-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous stem cell transplantation in the treatment of Hodgkin's disease].
  • BACKGROUND/AIM: High-dose chemotherapy with autologous stem cell transplantation (ASCT) has shown to produce long-term disease-free survival in patients with chemotherapy-sensitive Hodgkin disease.
  • The aim of the study was to evaluate efficacy of ASCT in the treatment of Hodgkin's disease.
  • METHODS: Between May 1997 and September 2008, 34 patients with Hodgkin's disease in median age of 25 (range 16-60) years, underwent ASCT.
  • Autologous SCT were performed as consolidation therapy in one poor-risk patients with complete response (CR) and in 10 patients in partial remission (PR) after induction chemotherapy (32.5%), for chemosensitive relapse (CSR 1 and CSR 2) in 47% patients and in 20.5% patients with chemoresistant disease (CRD).
  • All except one patient were in stage III/IV, extranodal site of disease had 24 patients and bulky disease had 10 patients.
  • However, when patients undergoing consolidation were analyzed separately from those in CSR, no significant difference in OS and PFS was observed according to the disease status at ASCT.
  • In univariate analysis for OS, PFS i DFS, extranodal site of disease and disease bulk had no predictive value.
  • The main cause of death was Hodgkin's disease.
  • CONCLUSION: Autologous SCT is efficient as consolidation therapy in high-risk patients and in chemosensitive relapse, but it has no benefit in patients with chemoresistant disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Rate. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678583.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


83. Franzke A, Koenecke C, Geffers R, Piao W, Hunger JK, Ganser A, Buer J: Classical Hodgkin's lymphoma: molecular evidence for specific alterations in circulating T lymphocytes. Tumour Biol; 2006;27(6):329-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classical Hodgkin's lymphoma: molecular evidence for specific alterations in circulating T lymphocytes.
  • OBJECTIVE: Impairment in cell-mediated immunity has long been recognized in classical Hodgkin's lymphoma (cHL).
  • The immunosuppressive environment at the tumor site and/or a primary T-cell defect may contribute to an ineffective immune clearance of Hodgkin/Reed-Sternberg (H/R-S) cells.
  • [MeSH-major] Hodgkin Disease / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antigens, CD3 / genetics. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes. Female. Gene Expression Profiling. Humans. Immunity, Cellular. Lymphocyte Count. Male. Middle Aged. Neoplasm Staging. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 17033203.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / RNA, Neoplasm
  •  go-up   go-down


84. Hwang KW, Woo OH, Koo BH, Yong HS, Kim A, Kang EY: Medullary carcinoma of the breast after radiation therapy for Hodgkin's disease in a young woman: report of a case. Surg Today; 2006;36(12):1105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medullary carcinoma of the breast after radiation therapy for Hodgkin's disease in a young woman: report of a case.
  • A 28-year-old woman who had received mantle-field radiation therapy for Hodgkin's disease (HD) almost 10 years earlier was referred to our hospital for investigation of a palpable mass in her left breast.
  • We review the literature on the secondary development of breast cancer after radiation therapy for HD.
  • [MeSH-major] Breast Neoplasms / etiology. Carcinoma, Medullary / etiology. Head and Neck Neoplasms / radiotherapy. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1674-81 [1403050.001]
  • [Cites] Australas Radiol. 1995 Aug;39(3):271-6 [7487764.001]
  • [Cites] Lancet Oncol. 2003 Apr;4(4):207-14 [12681264.001]
  • [Cites] Cancer Treat Rev. 2000 Aug;26(4):291-302 [10913384.001]
  • [Cites] Eur J Surg Oncol. 2003 Jun;29(5):475-9 [12798754.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1588-92 [9563465.001]
  • [Cites] Eur J Cancer. 1997 Dec;33(14):2315-20 [9616274.001]
  • (PMID = 17123141.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B, Zilberman I, Miron S, Leubovic A, Slavin S, Or R: Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant; 2005 Dec;36(12):1097-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.
  • We evaluated the effect of alefacept (Amevive), a novel dimeric fusion protein, in steroid resistant/dependent acute graft-versus-host-disease (aGVHD).
  • [MeSH-major] Drug Resistance. Graft vs Host Disease / drug therapy. Recombinant Fusion Proteins / therapeutic use. Steroids / pharmacology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Bone Marrow Transplantation. Child. Female. Gastrointestinal Tract / pathology. Humans. Infection. Liver / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Myelodysplastic Syndromes / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Primary Myelofibrosis / therapy. Skin / pathology. Skin Abnormalities / therapy. T-Lymphocytes / metabolism. Time Factors. Transplantation Conditioning. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247429.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 0 / Steroids; ELK3V90G6C / alefacept
  •  go-up   go-down


86. Chetaille B: [Mediastinal lymphomas: histopathology]. Rev Pneumol Clin; 2010 Feb;66(1):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three main entities summarize this pathology: T lymphoblastic lymphoma, mediastinal (thymic) diffuse large B cell lymphoma, and classical Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, Non-Hodgkin / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Child. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Mediastinum / pathology. Mediastinum / surgery. Neoplasm Invasiveness. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prognosis. Thymus Neoplasms / diagnosis. Thymus Neoplasms / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010. Published by Elsevier Masson SAS.
  • (PMID = 20207293.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 2
  •  go-up   go-down


87. Ferrario A, Radaelli F, Goldaniga M, F FG, Olivero B, Rossi F, Baldini L: ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma. Leuk Res; 2010 Oct;34(10):e280-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • [MeSH-minor] Adult. Benzamides. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Imatinib Mesylate. Male. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Recurrence. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20605208.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8A1O1M485B / Imatinib Mesylate; ABVD protocol
  •  go-up   go-down


88. Benetatos L, Alymara V, Vassou A, Bourantas KL: Malignancies in beta-thalassemia patients: a single-center experience and a concise review of the literature. Int J Lab Hematol; 2008 Apr;30(2):167-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thalassemia represents the world's most common monogenic disease, characterized by absence of or decreased globin chain production.
  • We report three cases of cancer (non-Hodgkin lymphoma, Hodgkin disease, and seminoma) in thalassemic patients.
  • [MeSH-minor] Adult. Female. Hodgkin Disease / complications. Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Radiotherapy, Adjuvant. Seminoma / complications. Seminoma / diagnosis. Seminoma / therapy. Testicular Neoplasms / complications. Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Thalassemia.
  • Genetic Alliance. consumer health - Beta Thalassemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333849.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


89. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most patients had bulky disease: three had a diameter >5 cm and eight a diameter >10 cm.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Registries. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


90. Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M: Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. Oncol Rep; 2005 Oct;14(4):933-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients].
  • Fifty-five patients received IEV for a disease that was refractory to conventional induction regimens, or that was in first or second relapse; 4 patients were treated with IEV while in complete response (CR) after chemotherapy in order to mobilise peripheral blood stem cells (PBSCs).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epirubicin / administration & dosage. Etoposide / administration & dosage. Hodgkin Disease / drug therapy. Ifosfamide / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Multiple Myeloma / drug therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / biosynthesis. Carmustine / administration & dosage. Cytarabine / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Odds Ratio. Podophyllotoxin / administration & dosage. Recurrence. Remission Induction. Time Factors. Transplantation Conditioning / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142354.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD34; 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; BEAM protocol
  •  go-up   go-down


91. Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C, Nordic Lymphoma Group: Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma; 2008 Jan;49(1):102-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.
  • The purpose of this phase II randomized trial was to evaluate the effect and safety of interferon-alpha2a (IFN) in combination with extended dosing rituximab in patients with symptomatic, advanced indolent lymphoma responding to a standard single course of rituximab.
  • Overall, 26 out of the 52 patients who achieved CR underwent minimal residual disease (MRD) evaluation.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Interferon-alpha / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Humans. Middle Aged. Neoplasm, Residual / diagnosis. Neutropenia / chemically induced. Recombinant Proteins. Remission Induction. Rituximab. Sweden. Thrombocytopenia / chemically induced

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2008 Jan;49(1):8-9 [18203002.001]
  • (PMID = 18203019.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Interferon-alpha; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


92. Metzger ML, Hudson MM, Krasin MJ, Wu J, Kaste SC, Kun LE, Sandlund JT, Howard SC: Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer; 2010 Sep 15;116(18):4376-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.
  • BACKGROUND: Pediatric Hodgkin lymphoma (HL) is a highly curable disease; however, prognostic factors for the survival of patients who develop recurrent disease have not been clearly defined.
  • Fifteen patients developed progressive disease during therapy, 14 patients relapsed early, and 21 patients relapsed late.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 1993 Apr;11(4):704-11 [8478664.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1137-45 [8443375.001]
  • [Cites] Radiology. 1997 Jun;203(3):795-800 [9169707.001]
  • [Cites] Radiology. 1998 Feb;206(2):475-81 [9457202.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):289-95 [9602263.001]
  • [Cites] Bone Marrow Transplant. 1998 Aug;22(3):265-71 [9720740.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3101-9 [10506605.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4532-40 [15542804.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Nov;26(11):740-5 [15543009.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):363-72 [16042685.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6181-9 [16135485.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Haematologica. 2006 Apr;91(4):475-81 [16585014.001]
  • [Cites] Haematologica. 2006 Apr;91(4):482-9 [16585015.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):189-95 [16601441.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):759-67 [16871391.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72 [17084370.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):60-7 [17021808.001]
  • [Cites] Radiology. 2007 Jul;244(1):257-62 [17581905.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):230-42 [17591570.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Blood. 2001 Jan 15;97(2):404-9 [11154216.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:112-6 [12078891.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2026-33 [12743158.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Br J Haematol. 1992 Jun;81(2):197-202 [1643017.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2351-61 [8246024.001]
  • (PMID = 20564743.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R37 CA036401-24; United States / NCI NIH HHS / CA / CA-60419; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA078224-10; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA-36401; United States / NIGMS NIH HHS / GM / GM061393-100007; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA036401-24; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA078224-10; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; United States / NIGMS NIH HHS / GM / U01 GM061393-100007; United States / NIGMS NIH HHS / GM / GM-61393; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS189726; NLM/ PMC2936658
  •  go-up   go-down


93. Aversa SM, Trentin C, Sorarů M, Di Bona E, Marino D, Canova F, Salvagno L, Adami F: Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma. Leuk Lymphoma; 2009 Jul;50(7):1214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacology. Bleomycin / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Mechlorethamine / therapeutic use. Prednisone / therapeutic use. Remission Induction. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use


94. Arotiba JT, Akadiri OA, Okeke LI, Obimakinde OS, Fasola AO, Okoje VN, Kolude B: Multiple malignant lesions involving the orofacial region: a case report. Afr J Med Med Sci; 2006 Sep;35(3):375-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine needle aspiration cytology (FNAC) of the parotid lesion and incisional biopsy of the gingival lesion were reported as Lymphoblastic lymphoma and Non Hodgkin's Lymphoma respectively.
  • The patient however died due to a number of intercurrent illnesses and rapid deterioration consequent on his disease condition.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphoma, Non-Hodgkin / pathology. Neoplasms, Multiple Primary / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Gingiva / pathology. Humans. Male. Parotid Gland / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312748.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


95. Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K: Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol; 2008 Sep;83(9):721-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
  • Epstein-Barr virus (EBV)-associated T/NK-cell lymphoproliferative disease (LPD) has been linked to several different disorders.
  • There are reports, however, that hematopoietic stem cell transplantation (HSCT) can cure this disease.
  • There were 42 cases of chronic active EBV infection (CAEBV), 10 cases of EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH), and 22 cases of EBV-associated lymphoma/leukemia (EBV-lymphoma/leukemia).
  • Of those with CAEBV, 54% had the EBV-infected T-cell type and 59% with EBV-lymphoma/leukemia had the EBV-infected NK-cell type.
  • Most patients with EBV-HLH and EBV-lymphoma/leukemia received allo-HSCT within 1 year after onset compared to only 14% of patients with CAEBV.
  • The event-free survival (EFS) rate following allo-HSCT was 0.561 +/- 0.086 for CAEBV, 0.614 +/- 0.186 for EBV-HLH, and 0.309 +/- 0.107 for EBV-lymphoma/leukemia.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chronic Disease. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Japan / epidemiology. Killer Cells, Natural / pathology. Leukemia, Large Granular Lymphocytic / epidemiology. Leukemia, Large Granular Lymphocytic / pathology. Leukemia, Large Granular Lymphocytic / surgery. Leukemia, Large Granular Lymphocytic / virology. Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. T-Lymphocytes / pathology. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18626884.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Pohl D: Epstein-Barr virus and multiple sclerosis. J Neurol Sci; 2009 Nov 15;286(1-2):62-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EBV is the etiological agent of infectious mononucleosis (Pfeiffer's disease).
  • Furthermore, diverse malignancies such as Burkitt and Hodgkin lymphoma have been associated with EBV.
  • MS is currently regarded as a disease with multifactorial etiology, EBV being one possible factor in MS manifestation: Infectious mononucleosis has been shown to increase the risk of developing MS later in life.
  • EBV seroprevalence rates are higher in MS as compared to controls, in adult as well as in pediatric MS patients.

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361810.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 45
  •  go-up   go-down


97. Gilheeney SW, Lyden DC, Sgouros S, Antunes N, Gerald W, Kramer K, Lis E, Meyers P, Rosen N, Thaler HT, Trippett T, Wexler L, Dunkel IJ: A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer; 2007 Sep;49(3):261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-one patients were evaluable for response; 1 had a partial response (Hodgkin disease), 1 demonstrated stable disease (neuroendocrine tumor), and 19 had progressive disease.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cyclophosphamide / pharmacology. Dose-Response Relationship, Drug. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Infant. Male. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16972243.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


98. Habek M, Brinar VV, Hajnsek S: The association of multiple sclerosis and Hodgkin's disease: the role of Epstein-Barr virus infection. Mult Scler; 2008 Mar;14(2):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of multiple sclerosis and Hodgkin's disease: the role of Epstein-Barr virus infection.
  • We present a 21-year-old male patient with a history of EBV-related infectious mononucleosis in puberty and Hodgkin's disease two years previously treated with irradiation and chemotherapy.
  • There were no signs of Hodgkin's disease relapse.
  • In the next three years he had three more bouts of the disease and he was diagnosed with relapse-remitting MS.
  • There is evidence of EBV involvement in MS pathogenesis; the association of MS with EBV-related infectious mononucleosis and Hodgkin's disease being just one of them.
  • Although there are many unanswered questions, it is clear that without EBV seropositivity MS in adults is extremely rare.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / complications. Multiple Sclerosis, Relapsing-Remitting / complications. Multiple Sclerosis, Relapsing-Remitting / virology
  • [MeSH-minor] Adult. Central Nervous System / pathology. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208872.001).
  • [ISSN] 1352-4585
  • [Journal-full-title] Multiple sclerosis (Houndmills, Basingstoke, England)
  • [ISO-abbreviation] Mult. Scler.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Jhamb R, Gupta N, Garg S, Kumar S, Gulati S, Mishra D, Beniwal P: Diffuse lymphomatous infiltration of kidney presenting as renal tubular acidosis and hypokalemic paralysis: case report. Croat Med J; 2007 Dec;48(6):860-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal biopsy was consistent with the diagnosis of non-Hodgkin lymphoma (B cell type).
  • Renal involvement in lymphoma is usually subclinical and clinically overt renal disease is rare.
  • [MeSH-major] Acidosis, Renal Tubular / etiology. Hypokalemia / etiology. Kidney Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Paralysis / etiology
  • [MeSH-minor] Acid-Base Equilibrium. Adult. Antigens, CD19 / metabolism. Antigens, CD20 / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Hepatomegaly / pathology. Hepatomegaly / ultrasonography. Humans. Kidney / radiography. Kidney / surgery. Muscle Weakness / etiology. Potassium Chloride / therapeutic use. Prednisone / administration & dosage. Prednisone / therapeutic use. Splenomegaly / pathology. Splenomegaly / ultrasonography. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - paralysis.
  • Genetic Alliance. consumer health - Renal tubular acidosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Paralysis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. POTASSIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nephrol Dial Transplant. 2004 Oct;19(10):2657-60 [15388825.001]
  • [Cites] Ann Intern Med. 1970 Mar;72(3):379-82 [5467127.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] J Am Soc Nephrol. 1997 Aug;8(8):1348-54 [9259365.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):748-53 [3524795.001]
  • [Cites] Indian J Pathol Microbiol. 1993 Jan;36(1):61-4 [8354558.001]
  • [Cites] Clin Nephrol. 1994 Sep;42(3):163-9 [7994934.001]
  • [Cites] J Assoc Physicians India. 1985 Sep;33(9):565-8 [4093400.001]
  • (PMID = 18074421.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 5J49Q6B70F / Vincristine; 660YQ98I10 / Potassium Chloride; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC2213800
  •  go-up   go-down


100. Shim HK, Lee WW, Park SY, Kim H, Kim SE: Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma. Oncol Res; 2009;17(7):331-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between FDG uptake and expressions of glucose transporter type 1, type 3, and hexokinase-II in Reed-Sternberg cells of Hodgkin lymphoma.
  • Reed-Sternberg (R-S) cells are the main tumor cells of Hodgkin lymphoma (HL).
  • In conclusion, high expressions of Glut-1 in R-S cells may play a crucial role for the high FDG uptake in Hodgkin lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Glucose Transporter Type 1 / metabolism. Glucose Transporter Type 3 / metabolism. Hexokinase / metabolism. Hodgkin Disease / metabolism. Hodgkin Disease / radionuclide imaging. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Female. Glucose Transporter Type 2 / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Positron-Emission Tomography. Reed-Sternberg Cells / radionuclide imaging. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408578.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Glucose Transporter Type 2; 0 / Glucose Transporter Type 3; 0 / Radiopharmaceuticals; 0 / SLC2A2 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.1.1 / Hexokinase
  •  go-up   go-down






Advertisement